

Jabir 01 May 2007

**Curriculum Vitae
JAMILA FINNEY, L.P.N., R.A.**

Business Address:

National Clinical Research, Inc
2809 Emerywood Parkway
Suite 140
Richmond, VA 23294
804-672-2133 ext. 37

EDUCATION

March 1997 St. Mary's School of Practical Nursing
 Henrico County
 Highland Springs, VA

PROFESSIONAL EXPERIENCE

Oct 2006 – present Research Assistant
 National Clinical Research, Inc.
 Richmond, VA

April 2004 – Oct 2006 LPN
 Children's Hospital
 Richmond, VA

Sep 1997 – March 2004 LPN
 St. Mary's Hospital
 Richmond, VA

Aug 1998 – Mar 1999 LPN
 Mid-Atlantic Home Health
 Midlothian, VA

CERTIFICATIONS

BCLS Certification

CLINICAL RESEARCH EXPERIENCE

Phase 3 multi-center, double-blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents, Pfizer/Pharmanet (Protocol A5091043), Jul04.

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia, Merck (Protocol 020), Dec05.

A Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination AEGR-733 and Ezetimibe vs. Monotherapy in Subjects with Moderate Hypercholesterolemia, Aegerion/Pharmanet (Protocol 733-001), Mar06.

A Multicenter, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of MK-0859 in Patients with primary Hypercholesterolemia or Mixed Hyperlipidemia, Merck (Protocol 859-003), Jun06.

Curriculum Vitae
Jamila Finney, R.A.
Page 2 of 3

Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK-0524A versus Niacin Extended-Release, Merck (Protocol 054), Aug06.

Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK-0524A versus Niacin Extended-Release, Merck (Protocol 054), Aug06.

A Phase 2b Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating The Efficacy And Safety Of PD-0299685 For The Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause, Pfizer/ICON (Protocol A4291023), Aug06.

A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy from Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density, Amgen/Quintiles (Protocol 20050234), Aug06.

Effects of Chronic Consumption of Rebaudioside a on Glucose Homeostasis in Men and Women with Type 2 Diabetes Mellitus, Cargill/Provident (PRV-06007), Nov06.

A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/day Lacosamide Tablets in Subjects with Signs and Symptoms Associated with Fibromyalgia Syndrome, Schwartz/INC Research (Protocol SP887), Nov06.

Acute and Chronic Effects of Rebaudioside A on Blood Pressure in Apparently Healthy Men and Women, Cargill/Provident (Protocol PRV 06008), Dec06.

A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease, Biomarin (Protocol PAD-001), Dec06.

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects with Low HDL-C Levels, Akros/Omnicare (Protocol AT302-U-06-003), Dec06.

An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects with Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003, Akros/Omnicare (Protocol AT302-U-06-004), Dec06.

A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout, Tap (Protocol F-GT06-153), Jan07.

A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200mg OD) versus placebo with cilostazol, 100mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II, Sanofi (Protocol DFI6174 (ACCELA)), Jan07.

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Clotrimazole 1% Creams in Patients with Interdigital Tinea Pedis, Novum (Protocol GLK612 (Study No. 70644004)), Feb07.

OPTIMIZE: A Study Evaluating the Co-Administration of Niaspan® (niacin extended-release) Caplet for Flexible Titration in Combination with Aspirin to Minimize Flush, KOS (Protocol 016-10-06 CR), Feb07.

A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid (ASA), Astra Zeneca (Protocol OBELIX D961FC00003), Mar07.

